A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515316-44-00

Acronym

79635322MMY1002

Enrollment

Registered

2024-12-16

Start date

2025-02-24

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026